Cargando…
Safety of targeting ROR1 for cancer immunotherapy with chimeric antigen receptor-modified T cells in a primate model
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288622/ http://dx.doi.org/10.1186/2051-1426-2-S3-P3 |
| _version_ | 1782351996373696512 |
|---|---|
| author | Berger, S Carolina Sommermeyer, Daniel Hudecek, Michael Berger, Michael Balakrishnan, Ashwini Paskiewicz, Paulina Kosasih, Paula Rader, Christoph Riddell, Stanley |
| author_facet | Berger, S Carolina Sommermeyer, Daniel Hudecek, Michael Berger, Michael Balakrishnan, Ashwini Paskiewicz, Paulina Kosasih, Paula Rader, Christoph Riddell, Stanley |
| author_sort | Berger, S Carolina |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4288622 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-42886222015-01-15 Safety of targeting ROR1 for cancer immunotherapy with chimeric antigen receptor-modified T cells in a primate model Berger, S Carolina Sommermeyer, Daniel Hudecek, Michael Berger, Michael Balakrishnan, Ashwini Paskiewicz, Paulina Kosasih, Paula Rader, Christoph Riddell, Stanley J Immunother Cancer Poster Presentation BioMed Central 2014-11-06 /pmc/articles/PMC4288622/ http://dx.doi.org/10.1186/2051-1426-2-S3-P3 Text en Copyright © 2014 Berger et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Berger, S Carolina Sommermeyer, Daniel Hudecek, Michael Berger, Michael Balakrishnan, Ashwini Paskiewicz, Paulina Kosasih, Paula Rader, Christoph Riddell, Stanley Safety of targeting ROR1 for cancer immunotherapy with chimeric antigen receptor-modified T cells in a primate model |
| title | Safety of targeting ROR1 for cancer immunotherapy with chimeric antigen receptor-modified T cells in a primate model |
| title_full | Safety of targeting ROR1 for cancer immunotherapy with chimeric antigen receptor-modified T cells in a primate model |
| title_fullStr | Safety of targeting ROR1 for cancer immunotherapy with chimeric antigen receptor-modified T cells in a primate model |
| title_full_unstemmed | Safety of targeting ROR1 for cancer immunotherapy with chimeric antigen receptor-modified T cells in a primate model |
| title_short | Safety of targeting ROR1 for cancer immunotherapy with chimeric antigen receptor-modified T cells in a primate model |
| title_sort | safety of targeting ror1 for cancer immunotherapy with chimeric antigen receptor-modified t cells in a primate model |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288622/ http://dx.doi.org/10.1186/2051-1426-2-S3-P3 |
| work_keys_str_mv | AT bergerscarolina safetyoftargetingror1forcancerimmunotherapywithchimericantigenreceptormodifiedtcellsinaprimatemodel AT sommermeyerdaniel safetyoftargetingror1forcancerimmunotherapywithchimericantigenreceptormodifiedtcellsinaprimatemodel AT hudecekmichael safetyoftargetingror1forcancerimmunotherapywithchimericantigenreceptormodifiedtcellsinaprimatemodel AT bergermichael safetyoftargetingror1forcancerimmunotherapywithchimericantigenreceptormodifiedtcellsinaprimatemodel AT balakrishnanashwini safetyoftargetingror1forcancerimmunotherapywithchimericantigenreceptormodifiedtcellsinaprimatemodel AT paskiewiczpaulina safetyoftargetingror1forcancerimmunotherapywithchimericantigenreceptormodifiedtcellsinaprimatemodel AT kosasihpaula safetyoftargetingror1forcancerimmunotherapywithchimericantigenreceptormodifiedtcellsinaprimatemodel AT raderchristoph safetyoftargetingror1forcancerimmunotherapywithchimericantigenreceptormodifiedtcellsinaprimatemodel AT riddellstanley safetyoftargetingror1forcancerimmunotherapywithchimericantigenreceptormodifiedtcellsinaprimatemodel |